Preterm Delivery Risk Prediction by Measurement of Prenatal Serum Screening Markers

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

UNKNOWN

Total Enrollment

2000 participants

Study Classification

OBSERVATIONAL

Study Start Date

2010-03-31

Study Completion Date

2012-07-31

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

This protocol seeks to longitudinally collect blood samples from a cohort of pregnant women. The biological specimens will be used to determine the predictive power of biochemical markers routinely used in Down syndrome screening in the assessment of patient's risk of preterm delivery.

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

Proteomic Assessment of Preterm Birth

NCT01371019

Preterm Birth

COMPLETED

A New Prenatal Blood Test for Down Syndrome

NCT00877292

Down Syndrome Trisomy 21

COMPLETED

A Multicenter Assessment of a Spontaneous Preterm Birth Risk Predictor

NCT02787213

Preterm Birth

COMPLETED

Prenatal Screening for Down Syndrome With DNAFirst

NCT01966991

Trisomy 21 Trisomy 18 Trisomy 13 +1 more

COMPLETED

Development of a Prenatal Test for Fetal Aneuploidy Detection

NCT01451671

Fetal Complications

COMPLETED

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

The study will investigate whether the levels of individual maternal serum screening biomarkers, their combinations or temporal changes in the level can be associated with an increased risk of preterm delivery. Blood samples at three time points in pregnancy will be collected from the study participants. The first two blood draws will be timed to coincide with the first and second trimester maternal serum testing. The third blood draw will coincide with the screening for gestational diabetes. Pregnancy outcome information will be collected from the physicians and linked to the subject samples.

Subject samples from a case-control patient group will be analyzed by the serum screening biochemical assay. Statistical analyses will be performed to achieve the study objectives.

NOTE: This study is recruiting in Florida, USA. The laboratory data coordination is being performed in Massachusetts, USA and New Mexico, USA. New study locations will be identified on an ongoing basis.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Preterm Delivery

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Observational Model Type

CASE_CONTROL

Study Time Perspective

PROSPECTIVE

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* The participant understands the nature of the study and its requirements. To this end, we will require that the participants have command of the English language.
* The participant consents to and signs the approved consent form.
* The participant is 18 years of age or older.
* The participant has a singleton pregnancy.
* The participant is planning on continuing the pregnancy.
* The participant has intent to clinically test for Down syndrome risk.
* The participant consents to the study at the first trimester of her pregnancy.
* The participant understands the nature of the study and its requirements. To this end, we will require that the participants have command of either the English or Spanish language.